The question
AOD-9604 weight-loss claims should be assessed against the human trial record, not only a proposed fat-metabolism mechanism. FDA's review describes a larger obesity study that failed to show statistically significant weight loss over placebo at its reported endpoints. That is a substantial limitation for claims of established effectiveness. FDA AOD-9604 review.
Follow the result back to its source
FDA's 2024 evaluation cites a sponsor disclosure about the OPTIONS study, described as involving 536 people and a diet-and-exercise program. The disclosure reported that differences from placebo at 12 and 24 weeks did not reach statistical significance. FDA also noted that the study's design details and preliminary efficacy results did not appear to have been published in the medical literature. This is a regulator's account of sponsor-reported results, not a fully published efficacy trial being independently reanalyzed here. FDA review, printed page 22.
That source trail matters. A company announcement can report an important negative finding, but it may not provide the methods, missing-data analysis and complete results available in a full trial report. A responsible summary should retain both the result and the limits of access to it.
Weight loss during a study is not automatically a drug effect
Suppose participants lose weight after entering a study. They may also have changed their eating or activity, received additional support, or experienced ordinary variation. A placebo comparison helps separate those shared changes from an additional effect attributable to the intervention.
This is why a graph in which every group loses weight can still fail to establish the tested treatment's advantage. The relevant question is not simply whether the treated group improved. It is whether the difference between groups supports the claim, with adequate precision and a clinically meaningful size.
A nonsignificant result also does not prove the true effect is exactly zero. It means the reported comparison did not establish the advertised benefit. Replacing that uncertainty with a confident success story would misrepresent the evidence.
US status and safety are separate questions
FDA's evaluation identifies AOD-9604 free base and acetate as ingredients without an FDA-approved drug product. FDA review. Its current safety page flags limited information and potential immune reactions; reported serious events have uncertain causality. FDA safety assessment, checked September 25, 2026.
Do not turn a negative efficacy finding into a claim that a compound is harmless. Benefit and harm require separate evaluation. Likewise, changing the route or formulation does not automatically rescue a failed efficacy claim; the new preparation needs relevant evidence of its own.
What a useful future update would include
Look for a prospectively described human comparison with the exact preparation, clearly reported participant flow, the planned weight outcome, and adverse-event follow-up. A testimonial cannot fill those gaps. For an example of reading direct comparative evidence, see tirzepatide versus semaglutide. Our peptide introduction explains the broader terminology.
Sources & further reading
Research context last reviewed September 25, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
